PhaseBio Pharmaceuticals

NasdaqGM:PHAS Stock Report

Mkt Cap: US$8.8m

We’ve recently updated our valuation analysis.

PhaseBio Pharmaceuticals Valuation

Is PHAS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PHAS?

Other financial metrics that can be useful for relative valuation.

PHAS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue7.8x
Enterprise Value/EBITDA-0.06x
PEG Ration/a

Price to Sales Ratio vs Peers

How does PHAS's PS Ratio compare to its peers?

PHAS PS Ratio vs Peers
The above table shows the PS ratio for PHAS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average7.8x
CLXT Calyxt
LOGC LogicBio Therapeutics
XBIO Xenetic Biosciences
APVO Aptevo Therapeutics
PHAS PhaseBio Pharmaceuticals

Price-To-Sales vs Peers: PHAS is expensive based on its Price-To-Sales Ratio (10.7x) compared to the peer average (7.8x).

Price to Earnings Ratio vs Industry

How does PHAS's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: PHAS is good value based on its Price-To-Sales Ratio (10.7x) compared to the US Biotechs industry average (13.2x)

Price to Sales Ratio vs Fair Ratio

What is PHAS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PHAS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.7x
Fair PS Ratio0x

Price-To-Sales vs Fair Ratio: Insufficient data to calculate PHAS's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of PHAS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PHAS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PHAS's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

  • Take a look at our analysis of PHAS's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.